Smarca2/4 inhibition as a strategy to treat tumors that harbor aberrant baf assemblies

A method of treating cancer in a subject in need thereof, the method comprising administering to the subject a compound having a structure represented by a formula:

• wherein R1 is selected from hydrogen and C1-C4 alkyl;
• wherein each of R2a, R2b, R2c, R2d, and R2e is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• wherein R3 is selected from hydrogen and C1-C4 alkyl;
• wherein each of R4a and R4b is independently selected from hydrogen, halogen, and C1-C4 alkyl;
• wherein each of R5a, R5b, and R5c is independently selected from hydrogen, halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl;
• wherein each of R6a and R6b is independently selected from hydrogen and halogen;
• and
• wherein Cy1 is a C3-C8 cycloalkyl substituted with 0, 1, 2, 3, or 4 groups independently selected from halogen, —CN, —NH2, —OH, —NO2, C1-C4 alkyl, C2-C4 alkenyl, C1-C4 haloalkyl, C1-C4 cyanoalkyl, C1-C4 hydroxyalkyl, C1-C4 haloalkoxy, C1-C4 alkoxy, C1-C4 alkylamino, (C1-C4)(C1-C4) dialkylamino, and C1-C4 aminoalkyl, provided that at least one of R6a and R6b is halogen, or a pharmaceutically acceptable salt thereof, wherein the cancer comprises a tumor having a mutant BAF chromatin remodeling complex.